Covid public health emergencies to end in May, but FDA's EUA authority will continue

Katherine Lewin

News Reporter

The Biden administration announced plans late yesterday to extend the Covid-19 national and public health emergencies until May 11, despite two Republican-led bills that are …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid public health emergencies to end in May, but FDA's EUA authority will continue

Katherine Lewin

News Reporter

Sign up to read this article for free.

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

CMS explains what went into its first round of drug price negotiations

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Covid pub­lic health emer­gen­cies to end in May, but FDA's EUA au­thor­i­ty will con­tin­ue

Katherine Lewin

News Reporter

Sign up to read this article for free.

more like this

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Covid public health emergencies to end in May, but FDA's EUA authority will continue

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

CMS explains what went into its first round of drug price negotiations

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties